People · Operator
Named in public records as an officer, director or promoter · active 2017–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Caelum Biosciences, Inc. | — | Biotechnology | Series A | $9.9M | $358.4M | 2017 |
Martin W. Goldman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Martin W. Goldman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Lindsay A. Rosenwald | 1 | 7 |
| Michael S. Weiss | 1 | 7 |
| Kenneth W. Cappell | 1 | 2 |
| Michael Spector | 1 | 2 |
| William W. Natbony | 1 | 1 |
| Jeffrey S. Paley | 1 | 1 |
| David W. Horin | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.